# **ENABLING USER FOR CONTINUOUS MONITORING AND DETECTION OF BLOOD FLUID LEVELS IN DIABATIC PATIENTS**

A PROJECT REPORT

# SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF THE DEGREE

OF

# **MASTER OF DESIGN** IN **PRODUCT DESIGN**

Submitted by

## **MOHAMMAD ZAKI (2K22/MDPD/03)**

Under the supervision of

**Dr. RAVINDRA SINGH**



**DEPARTMENT OF DESIGN** DELHI TECHNOLOGICAL UNIVERSITY (Formerly Delhi College of Engineering) Bawana Road, Delhi-110042

## **MAY, 2024**

## **DEPARTMENT OF DESIGN** DELHI TECHNOLOGICAL UNIVERSITY (Formerly Delhi College of Engineering) Bawana Road, Delhi-110042

#### **CANDIDATE'S DECLARATION**

I, MOHAMMAD ZAKI, Roll No – 2K22MDPD03, student of Master of Design (Department of Design), hereby declare that the project Dissertation titled "ENABLING USER FOR CONTINUOUS MONITORING AND DETECTION OF BLOOD FLUID LEVELS IN DIABATIC PATIENTS" which is submitted by me to the Department of Design, Delhi Technological University, Delhi in partial fulfilment of the requirement for the award of degree of Master of Design, is original and not copied from any source without proper citation. This work has not previously formed the basis for the award of any Degree, Diploma Associateship, Fellowship or other similar title or recognition.

Place: New Delhi Date: 02/05/2024

Mohammad Zaki

## **DEPARTMENT OF DESIGN** DELHI TECHNOLOGICAL UNIVERSITY (Formerly Delhi College of Engineering) Bawana Road, Delhi-110042

#### **CERTIFICATE**

I, hereby certify that the Project Dissertation titled "ENABLING USER FOR CONTINUOUS MONITORING AND DETECTION OF BLOOD FLUID LEVELS IN DIABATIC PATIENTS" which is submitted by MOHAMMAD ZAKI, Roll No. – 2K22MDPD03 here, Department of Design, Delhi Technological University, Delhi in partial fulfilment of the requirement for the award of the degree of Master of Design, is a record of the project work carried out by the students under my supervision. To the best of my knowledge this work has not been submitted in part or full for any Degree or Diploma to this University or elsewhere.

Place: New Delhi Date: 02/05/2024

Dr. Ravindra Singh

Assistant Professor Department of Design Delhi Technological University Delhi

## **DEPARTMENT OF DESIGN** DELHI TECHNOLOGICAL UNIVERSITY (Formerly Delhi College of Engineering) Bawana Road, Delhi-110042

#### **ACKNOWLEDGEMENT**

I, wish to express our sincerest gratitude to Prof. Ravindra Singh for his continuous guidance and mentorship that he provided us during the project. He showed us the path to achieve our targets by explaining all the tasks to be done and explained to us the importance of this project as well as its industrial relevance. He was always ready to help us and clear our doubts regarding any hurdles in this project. Without his constant support and motivation, this project would not have been successful.

Place: New Delhi Date: 02/05/2024

Mohammad Zaki

## **Abstract**

The project titled "Enabling User for Continuous Monitoring and Detection of Blood Fluid Levels" addresses the critical issue of diabetic ketoacidosis (DKA) through innovative solutions for continuous monitoring and early detection of blood fluid levels. DKA poses a life-threatening complication of diabetes, characterized by elevated blood ketone levels, metabolic acidosis, and dehydration. By comprehensively exploring DKA's pathophysiology, clinical manifestations, and management, this research aims to improve patient outcomes and enhance overall well-being.

The project delves into innovative diagnostics to enhance DKA detection. Two key approaches are highlighted: non-invasive breath analysis and sensitive electrochemical sensors. Non-invasive breath analysis introduces an alternative to traditional blood tests, enabling clinicians to detect early signs of DKA by analyzing volatile organic compounds (VOCs) in exhaled breath. Portable breath analyzers facilitate convenientmonitoring at home or in clinical settings. Additionally, sensitive electrochemical sensors are investigated for accurately measuring ketone concentrations in blood samples, providing rapid results for timely intervention.

Effective management of DKA necessitates practical tools for routine screening and intervention. The thesis discusses handheld blood ketone meters, enabling users to measure blood ketone levels with a small blood sample in realtime. Furthermore, automated urine test strip readers are explored to interpret test strip results objectively,enhancing accuracy and reliability by eliminating subjectivity and user error.

A groundbreaking contribution of this research is the development of a noninvasive device for continuous monitoring. Utilizing Short Wave Infrared (SWIR) and Long Wave Infrared (LWIR) technology, the device detects ketones and glucose levels in theskin without the need for blood samples or painful procedures. Users can simply place the device on their skin, receiving real-time readings, promising improved complianceand better management of DKA.

In conclusion, the thesis amalgamates scientific exploration, technological advancements, and practical solutions to enable users to monitor blood fluid levels continuously. By reducing the burden of invasive testing and enhancing early detection, it contributes to better diabetes management and overall patient well-being.

This research lays the foundation for further advancements in diabetes care, with implications for improving patient outcomes and enhancing quality of life.

## **Contents**

























## **List of Tables**



# **List of Figures**



## **List of Abbreviations**





## **Chapter 1**

## **INTRODUCTION**

### **1.1 DIABETES**

Diabetes mellitus stands as a chronic metabolic disorder marked by heightened blood sugar levels due to either inadequate insulin production, ineffective insulin utilization, or both. Insulin, a hormone produced by the pancreas, regulates blood sugar levels by facilitating glucose uptake into cells for energy production [1]. When this process malfunctions, it leads to hyperglycemia (high blood sugar), which, if uncontrolled, can result in severe complications.

The disease encompasses primarily two main types:

#### **1.1.1 Type 1 Diabetes**

Stemming from the autoimmune destruction of insulin-producing beta cells in the pancreas, this type involves little to no insulin production. It usually emerges early in life, though it can manifest at any age [2]. Those with type 1 diabetes necessitate lifelonginsulin therapy for survival.

#### **1.1.2 Type 2 Diabetes**

This variant typically develops gradually and is characterized by insulin resistance, wherein cells become less responsive to insulin's effects, coupled with relative insulin deficiency [2]. It's often linked with lifestyle factors like obesity, sedentary habits, and poor dietary choices, although genetics also wield significant influence.

#### **1.1.2 Diabetic Ketoacidosis (DKA)**

It emerges as a severe and potentially life-threatening complication, chiefly affecting individuals with type 1 diabetes, though it can also occur in type 2 diabetes under certain circumstances [3]. DKA ensues when there's a severe shortage of insulin, rendering the body unable to utilize glucose for energy. Consequently, the body resorts to breaking down fat for energy, yielding ketones, acidic compounds that accumulate inthe blood.

The cardinal features of DKA comprise:

- **Hyperglycemia**: Blood sugar levels typically surpass 250 mg/dL (13.9 mmol/L).
- **Ketosis**: Elevated ketone levels in the blood and urine.
- **Acidosis**: Ketone buildup leads to decreased blood pH, inducing metabolic acidosis.
- **Dehydration**: Excessive urination (polyuria) prompts fluid loss and dehydration.

Common DKA triggers encompass illness, infection, inadequate insulin therapy, and specific medications [4]. Symptoms include extreme thirst, frequent urination, abdominal discomfort, nausea, vomiting, rapid breathing, confusion, and fruitysmelling breath.

Prompt medical attention is imperative for DKA, as it can progress swiftly and culminate in coma or death if untreated [5]. Treatment typically entails intravenous fluidsto rectify dehydration, insulin therapy to lower blood sugar and halt ketone production,and electrolyte replacement to reinstate balance.

To sum up, while diabetes represents a chronic condition typified by elevated blood sugar levels, diabetic ketoacidosis embodies a severe and potentially lifethreatening complication, arising predominantly from insulin deficiency [6]. Timely recognition and intervention are paramount to avert serious consequences and enhance prognosis.

## **1.2 HISTORY**

The history of diabetes and diabetic ketoacidosis (DKA) stretches back thousands of years, with observations and treatments evolving over time.

Here's a brief overview:

#### **1.2.1 Ancient Observations**

Diabetes symptoms have been observed since ancient times, with early mentions found in ancient Egyptian medical texts around 1500 BCE. These texts described a condition characterized by excessive urination and weight loss [7]. Ancient Greek physicians, including Aretaeus of Cappadocia in the 2nd century CE, referred to this condition as

"diabetes," derived from the Greek word meaning "siphon" or "to pass through," reflecting the symptom of frequent urination.

#### **1.2.2 Early Understandings and Treatments**

Throughout history, diabetes was recognized mainly by its symptoms such as excessive thirst, frequent urination, and weight loss [8]. Treatments were often ineffective and sometimes peculiar, ranging from dietary restrictions to herbal remedies. The 19th century saw experimentation with pancreatic extracts, showing promise in alleviating diabetic symptoms and laying the groundwork for future discoveries [9].

#### **1.2.3 Discovery of Insulin**

A pivotal moment in diabetes history occurred in 1921 when Canadian researchers Frederick Banting and Charles Best discovered insulin at the University of Toronto. Their work involved extracting insulin from animal pancreases, offering a life-saving treatment for individuals with type 1 diabetes [10].

Insulin's discovery revolutionized diabetes treatment, transforming it from a fatal disease to a manageable condition. Banting and Best were awarded the Nobel Prize inPhysiology or Medicine in 1923 for their groundbreaking work.

#### **1.2.4 Understanding DKA**

Diabetic ketoacidosis (DKA) is a severe complication of diabetes characterized by high blood ketone levels, acidosis, and dehydration. It commonly occurs in individuals with type 1 diabetes due to insufficient insulin, leading to fat breakdown and ketone production [11]. Over time, medical understanding and management of DKA have improved, with early recognition and prompt treatment being crucial in preventing complications such as coma and death.

## **1.3 PATHOPHYSIOLOGY OF DKA**

DKA typically arises from either an absolute or relative deficiency of insulin, leading to various metabolic disruptions:

#### **1.3.1 Insulin Deficiency**

Insufficient insulin levels hinder glucose uptake and utilization by peripheral tissues, resulting in hyperglycemia. This deficit also triggers increased lipolysis in adipose tissue.

#### **1.3.2 Increased Lipolysis**

Reduced insulin action prompts the breakdown of triglycerides stored in adipocytes into free fatty acids and glycerol. These liberated fatty acids are then transported to the liver.

#### **1.3.3 Hepatic Ketogenesis**

Within the liver, free fatty acids undergo oxidation to form ketone bodies acetoacetate and beta-hydroxybutyrate—in a process termed ketogenesis. Hindered tissue utilization and impaired renal clearance cause the accumulation of these ketone bodies in the bloodstream.

#### **1.3.3 Acidosis**

The buildup of ketone bodies leads to a decline in blood pH, instigating metabolic acidosis. This is compounded by the loss of bicarbonate ions through urine as the body endeavors to counterbalance the acidosis.

The clinical manifestation of DKA typically encompasses:

- •**Polyuria and Polydipsia**: Elevated glucose levels trigger osmotic diuresis, resulting in increased urine output and thirst.
- •**Nausea and Vomiting**: Gastrointestinal symptoms may manifest due to metabolicacidosis.
- •**Abdominal Pain**: Individuals may experience diffuse and crampy abdominal discomfort.
- •**Kussmaul Breathing**: Deep, labored breathing (Kussmaul respirations) serves as acompensatory mechanism to lower blood pH by expelling carbon dioxide.
- •**Fruity Breath Odor**: The presence of acetone in the breath yields a distinctivefruity scent.

## **1.4 DIAGNOSIS OF DKA**

Diagnosing DKA involves a combination of clinical assessment and laboratory parameters:

- •**Hyperglycemia**: Blood glucose levels typically surpass 250 mg/dL (13.9 mmol/L).
- •**Ketosis**: Ketone bodies are detectable in urine (via dipstick) or blood (throughlaboratory measurement).
- •**Metabolic Acidosis**: Arterial blood gas analysis reveals a low pH (<7.3) anddiminished bicarbonate levels (<18 mEq/L).

## **1.5 TREATMENT OF DKA**

- •**Fluid Resuscitation**: Administration of intravenous fluids, typically isotonic saline, aims to restore intravascular volume and correct dehydration.
- **Insulin Therapy**: Initiation of continuous intravenous insulin infusion helps facilitate glucose uptake by cells and suppress further ketogenesis.
- •**Electrolyte Replacement**: As necessary, potassium and other electrolytes are replenished to address imbalances induced by insulin therapy and metabolic disruptions.
- •**Monitoring**: Continuous surveillance of blood glucose, electrolytes, and acidbasestatus is crucial for guiding treatment and averting complications.

### **1.6 COMPLICATIONS ASSOCIATED WITH DKA**

- •**Cerebral Edema**: Brain swelling, though rare, can be a potentially fatal complication, particularly in children, necessitating vigilant neurological monitoring.
- •**Electrolyte Imbalances**: During treatment, various electrolyte disturbances such as hypokalemia, hyperkalemia, and hyponatremia may arise.
- •**Acute Respiratory Distress Syndrome (ARDS):** Critically ill patients with DKAare susceptible to severe pulmonary complications like ARDS.
- •**Renal Dysfunction**: Dehydration, electrolyte imbalances, and acid-base disturbances can contribute to acute kidney injury.

### **1.7 DIABETES MELLITUS**

Diabetes Mellitus stands as a chronic metabolic disorder characterized by hyperglycemia arising from deficiencies in insulin secretion, insulin action, or both [12]. Itencompasses various types, including:

- •**Type 1 Diabetes**: Resulting from the autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency.
- •**Type 2 Diabetes**: Stemming from insulin resistance and relative insulin deficiency,often linked with obesity and lifestyle factors.
- •**Gestational Diabetes Mellitus (GDM)**: Manifesting during pregnancy due to hormonal fluctuations and insulin resistance, potentially impacting maternal and fetal health.

### **1.8 RISK FACTOR FOR DIABETES MELLITUS**

- •**Genetic Predisposition**: A family history of diabetes heightens the susceptibility todeveloping the condition.
- •**Obesity and Sedentary Lifestyle**: Excessive body weight and physical inactivitycontribute to insulin resistance and Type 2 diabetes.
- •**Age and Ethnicity**: Advancing age and specific ethnic backgrounds (e.g., AfricanAmerican, Hispanic/Latino, Native American) elevate diabetes risk.
- •**Gestational Factors**: Prior occurrences of gestational diabetes or polycystic ovarysyndrome (PCOS) raise the likelihood of Type 2 diabetes.

#### **1.9 LONG TERM COMPLICATIONS OF DIABETESMELLITUS**

- •**Macrovascular Complications**: Including cardiovascular ailments like coronary artery disease, stroke, and peripheral artery disease.
- •**Microvascular Complications**: Involving retinopathy, nephropathy, and neuropathy impacting the eyes, kidneys, and peripheral nerves, respectively.
- •**Diabetic Foot Complications**: Such as neuropathy, peripheral arterial disease,

and impaired wound healing, increasing susceptibility to foot ulcers and lower limb amputations.

•**Other Complications**: Erectile dysfunction, gastroparesis, and skin conditions represent additional diverse manifestations of diabetes mellitus.

## **Chapter 2**

## **RESEARCH**

### **2.1 RESEARCH PAPERS**

#### **2.1.1 Detecting Diabetic Ketoacidosis with Infection: Combating Life-**

#### **Threatening Emergency with Practical Diagnostic Tools**

Diabetic ketoacidosis (DKA) is a severe complication of diabetes mellitus that poses a significant threat to patient well-being when left untreated. Recent studies have indicated a mortality rate of approximately 2–5%, which can vary depending on factors such as age [13]. Insulin discontinuation and infections have been identified as primary contributors to DKA development. Among infections, bacterial ones like urinary tract infections and pneumonia are responsible for around half of all DKA cases [14].

Prompt identification of infections in DKA patients is crucial to prevent unnecessary antibiotic use and the emergence of antibiotic resistance. However, traditional bacterial culture methods are often time-consuming, delaying necessary interventions [15]. Toaddress this challenge, researchers have explored various septic markers to distinguishbetween DKA cases with and without infection, with the goal of refining diagnostic approaches and emphasizing the importance of early detection and intervention [16].

- •DKA manifests as a severe condition characterized by the production of ketone bodies, acidosis, and hypovolemia.
- •Triggers for DKA include insulin discontinuation and infections, with bacterial infections such as urinary tract infections and pneumonia being common precipitating factors.
- •The presence of an infection significantly increases mortality rates in individuals with DKA.
- •Accurate differentiation between DKA cases with and without concurrent infectionis essential for appropriate antibiotic use and the prevention of antibiotic resistance.
- •Various septic indicators and diagnostic methods, such as procalcitonin (PCT)

levels, serum lactate levels, white blood cell count, and the procalcitonin-to-lactate ratio (PLR), can aid in detecting infections in DKA patients.

#### **2.1.2 Breath Analysis for the In Vivo Detection of Diabetic**

#### **Ketoacidosis**

Analysis of volatile organic compounds (VOCs) in human breath has recently attracted considerable attention due to its potential for swiftly and noninvasively detecting various metabolic disorders [17]. The identification of ketones in breath and blood is vital for diagnosing and managing conditions such as diabetic ketoacidosis (DKA) in individuals with type 1 diabetes. Additionally, there is a growing necessity to detect euglycemic ketoacidosis in patients with type 1 or type 2 diabetes or heart failure who are receiving treatment with sodium-glucose transporter-2 inhibitors (SGLT2-i) [18]. Thisresearch evaluates the efficacy of colorimetry in discerning acetone and ethanol in exhaled breath, taking into account parameters like response time, pH, temperature, concentration, and dye selectivity. By employing a multidye system as suggested, thestudy achieved a detection limit of 0.0217 ppm for acetone and 0.029 ppm for ethanolwithin the 0.05–50 ppm range. A portable colorimetric device paired with a smartphone facilitated rapid and real-time measurement of relative red/green/blue values within 60 seconds, rendering it suitable for practical use [19]. This developed methodology shows promise for the swift and cost-efficient detection of ketones in patients with type 1 diabetes and DKA, as well as individuals with type 1 or type 2 diabetes or heart failure undergoing SGLT2-i treatment and euglycemic ketoacidosis [20].

- •The study effectively showcases a non-invasive approach for detecting diabetic ketoacidosis (DKA) through the analysis of volatile organic compounds present in human breath.
- •Researchers examined the efficacy of a multidye colorimetric system in identifying acetone and ethanol levels in exhaled breath, both of which serve as key indicators of DKA.
- •Furthermore, the study introduces a portable colorimetric device assisted by smartphones, facilitating the swift detection of ketones in breath samples. This

innovation holds significant promise for practical diabetes monitoring applications.

•Overall, this methodology presents a fast and cost-effective means for DKA detection, particularly advantageous in settings with limited resources.

## **2.1.3 Highly Sensitive Electrochemical Sensor for Diagnosis of Diabetic Ketoacidosis (DKA) by Measuring Ketone Bodies in Urine**

Introduction of a novel enzyme-coated gold electrode developed specifically for the electrochemical detection of acetylacetic acid (AcAc) levels in urine samples. The electrode incorporates a fixed layer comprising a combination of D-β-hydroxybutyrate dehydrogenase (HBDH) and nicotinamide adenine dinucleotide (NADH) as the sensing material. Its electroanalytical characteristics were thoroughly examined through cyclic voltammetry (CV) analysis [21]. The modified electrodes exhibit notable sensitivity to AcAc, displaying a linear increase in current corresponding to higher concentrations of AcAc. With a limit of detection (LOD) recorded at 6.25 mg/dL within the clinically significant range spanning from 6.25 to 100 mg/dL, the performance of the electrode was evaluated using a pool of 20 patient samples [22]. Comparative analysis with outcomes acquired from a commercially available kit reveals a significant concurrence, thereby affirming the electrode's utility for on-thespot monitoring of essential biochemical parameters such as urine ketone levels.

- •The research outlines the development of an enzyme-coated gold electrode for electrochemical detection of acetylacetic acid (AcAc) in urine, a crucial aspect of diabetic ketoacidosis (DKA) monitoring.
- •Employing a multi-layer enzyme modification strategy, the sensor specifically targets AcAc, a significant ketone body, presenting a convenient, swift, and recyclable approach for urine ketone detection.
- •Through a comparative analysis with commercial kits using 20 patient samples, the electrode showed commendable correlation, suggesting its viability as a point-ofcare tool for DKA management.

## **2.1.4 Advanced selective non-invasive ketone body detection sensors based on ionophores**

Investigated innovative molecules and methods suitable for detecting ketone bodies at minimal concentrations. Ketone bodies are indicative of various conditions, including type 1 diabetes, childhood hypo-glycemia-growth hormone deficiency, toxic inhalation, and metabolic alterations [23]. The study introduces specialized sensors designed to detect ketone bodies, employing environmentally friendly organic molecules in conjunction with Lewis acid additives. Computational simulations using Density Functional Theory (DFT) were conducted on the sensor molecules, namely Bromo-acetonaphthone tungstate (BANT) and acetonaphthophenyl ether propiono hydroxyl tungstate (APPHT). The simulations revealed relaxed geometries devoid of symmetry attributes and specific coordination, thereby enhancing sensitivity to ketonebodies. A portable sensing apparatus was developed, wherein the detection medium containing low concentrations of ketone bodies exhibits discernible color changes visible to the naked eye and distinctive irradiance under UV light [24]. Furthermore, a range of analytical techniques such as RGB analysis, electrochemical tests, scanning electronmicroscopy (SEM) characterization, Fouriertransform infrared spectroscopy (FTIR),absorbance, and emission spectroscopy were employed to validate the ketone sensitivity.

- •The research presents novel environmentally friendly organic molecules combined with Lewis acid additives for the specific detection of ketone bodies. Ketone bodies play a crucial role in health monitoring due to their association with conditions such as type 1 diabetes and alterations in body metabolism.
- •Density functional theory (DFT) simulations were conducted to analyze the sensor molecules, namely Bromo-acetonaphthone tungstate (BANT) and acetonaphthophenyl ether propiono hydroxyl tungstate (APPHT). These simulations revealed optimized geometries, thereby enhancing the sensitivity of the molecules towards ketone bodies.
- •A portable sensing device was engineered, exhibiting color variations visible to the naked eye and distinct irradiance patterns under UV light exposure upon interaction with ketone bodies. Additionally, the paper elucidates various analytical techniques

including RGB analysis, electrochemical assays, scanning electron microscopy (SEM) characterization, Fourier-transform infrared spectroscopy (FTIR), absorbance spectroscopy, and emission spectroscopy to corroborate the efficacy and sensitivity of the developed molecules.

## **2.1.5 Blood Ketones: Measurement, Interpretation, Limitations, and Utility in the Management of Diabetic Ketoacidosis**

Investigated innovative molecules and methods suitable for detecting ketone bodies at minimal concentrations. Ketone bodies are indicative of various conditions, including type 1 diabetes, childhood hypo-glycemia-growth hormone deficiency, toxic inhalation, and metabolic alterations [25]. The study introduces specialized sensors designed to detect ketone bodies, employing environmentally friendly organic molecules in conjunction with Lewis acid additives. Computational simulations using Density Functional Theory (DFT) were conducted on the sensor molecules, namely Bromo-acetonaphthone tungstate (BANT) and acetonaphthophenyl ether propiono hydroxyl tungstate (APPHT). The simulations revealed relaxed geometries devoid of symmetry attributes and specific coordination, thereby enhancing sensitivity to ketonebodies. A portable sensing apparatus was developed, wherein the detection medium containing low concentrations of ketone bodies exhibits discernible color changes visible to the naked eye and distinctive irradiance under UV light [26]. Furthermore, a range of analytical techniques such as RGB analysis, electrochemical tests, scanning electronmicroscopy (SEM) characterization, Fouriertransform infrared spectroscopy (FTIR),absorbance, and emission spectroscopy were employed to validate the ketone sensitivity.

Summary:

•Diabetic ketoacidosis (DKA) is a severe complication primarily observed in individuals with type 1 diabetes owing to a deficiency in insulin. This condition

involves a cascade of metabolic processes, ultimately leading to a shift from glucose-centered to ketone-centered management.

•An essential aspect highlighted in the management of DKA is the measurement of blood ketones, particularly β-hydroxybutyrate, utilizing hand-held meters. This method is favored over urine ketone testing due to its superior accuracy and the ability for real-time monitoring.

- •One noteworthy concern discussed in the paper is the emergence of euglycemic DKA linked with the use of SGLT-2 inhibitors, a class of drugs prescribed for type 2 diabetes. This underscores the importance of patient education regarding this risk.
- •Additionally, the paper addresses the cost-effectiveness of ketone meters despite their higher initial price compared to urine tests. This is justified by their potential to mitigate emergency visits and hospitalizations, ultimately saving healthcare resources in the long term.

## **2.1.6 Comparison of capillary blood ketone measurement by electrochemical method and urinary ketone in treatment of diabetic ketosis and ketoacidosisin children**

Our objective was to evaluate the comparative efficacy of capillary β-hydroxy butyrate (βOHB) measurement, a recently adopted practical approach, versus traditional urinary ketone measurement in monitoring the metabolic condition of patients undergoing therapy for diabetic ketoacidosis (DKA) and diabetic ketosis (DK) [27]. Patients admitted with DKA and DK were monitored using concurrent measurements of capillary βOHB through the electrochemical method (Medisense Optium, Abbott) and urinary ketone via a semi-quantitative method. Blood gases were sampled at intervals of 2–4 hours. Fourteen patients with DKA/DK (7 males and 7 females, mean age:  $9.2 \pm 4.2$  years) were enrolled, resulting in 50 concurrent measurements of capillary and urinary ketones. There was no discernible correlation between urinary ketone levels and blood pH ( $P = 0.06$ ) or HCO3 ( $P = 0.79$ ). However, a significant negative correlation was detected between capillary βOHB levels and blood pH ( $r =$  $-0.41$ , P < 0.05) as well as HCO3 (r =  $-0.35$ , P < 0.05). Initially and 3.3  $\pm$  1.4 hours post-treatment, no correlation was observed between capillary βOHB and urinary ketone levels, but a correlation emerged in the third samples taken  $7.8 \pm 2.0$  hours posttreatment ( $r = 0.8$ ,  $P < 0.05$ ). Capillary βOHB levels exhibited a robust correlation with the severity of acidosis (pH and HCO3). In gauging the patient's metabolic status and response to treatment, capillary βOHB measurement demonstrated greater sensitivity [28].

Summary:

- Capillary βOHB levels have demonstrated a robust correlation with the extent of acidosis, as evidenced by blood pH and HCO₃ levels, underscoring its superior sensitivity as an indicator of a patient's metabolic condition during treatment.
- Research findings reveal a significant inverse relationship between capillary βOHB levels and blood pH and HCO₃ levels, affirming its efficacy in reflectingthe severity of acidosis. Conversely, urinary ketone levels exhibit poor correlation with these parameters.
- In monitoring the metabolic status and progression during treatment for DKA, capillary βOHB measurement emerges as more efficacious compared to urinary ketone measurement.
- The investigation concludes that capillary blood βOHB measurement presentsitself as a pragmatic and dependable approach to DKA management. Its utilityextends to early detection and treatment of DKA episodes, as well as aiding patient selfmonitoring during periods of illness management.

## **2.1.7 Quantitative measurement of ketone bodies in urine using reflectometry**

Automated urine test strip readers now offer quantitative data reporting capabilities, allowing for the measurement of all ketone bodies present in urine, including acetone, acetoacetate, and 3-hydroxybutyrate. This study aimed to explore the feasibility of using these strips for such measurements, highlighting advantages like the ability to measure higher values due to low renal thresholds and reduced susceptibility to fluctuations. The investigation involved assessing the URISYS 2400 (Roche) quantitative reflectance data for the ketone reflectance field and comparing it with biochemical data from urine samples. A sample pre-treatment method involving 3 hydroxybutyrate dehydrogenase was utilized to successfully assay 3-hydroxybutyrate, a component typically unreactive on urine test strips. Reproducibility analysis showed within- and between-run reproducibility of the reflectance signal for high- and lowconcentration urine pools, with percentages ranging from 11.0-3.6% and 11.0-5.8% for acetoacetate, 8.2-9.2% and 10.4-16.1% for acetone, and 5.1-3.0% and 5.6-3.5% for

3-hydroxybutyrate, respectively. The lower limit of detection for acetoacetate was determined to be 0.13 mmol/L (CV=3.6%). A fair agreement was observed between data obtained from the test strips for ketones and colorimetrically determined acetoacetate values  $(r=0.90)$ . These findings indicate that quantitative ketone reflectance data obtained from urine test strips enable straightforward and rapid analysis, offering an affordable screening method for detecting ketone body production.

#### Summary:

- •Automated urine test strip readers have emerged as valuable tools for quantitatively measuring all ketone bodies present in urine, including acetone, acetoacetate, and 3 hydroxybutyrate.
- •Reflectometry, a technique utilized by these readers, holds promise for delivering more precise measurements owing to its low renal thresholds and reduced susceptibility to fluctuations. This attribute can prove particularly advantageous in monitoring ketone concentrations in diabetic patients, especially in emergency scenarios.
- In a recent study, the URISYS 2400, developed by Roche, was subjected to evaluation for its ability to provide quantitative reflectance data pertaining to ketone levels in urine. The researchers conducted a comparative analysis between the reflectance data obtained and the biochemical data derived from urine samples.
- •An interesting aspect of the study involved the utilization of sample pre-treatment with 3-hydroxybutyrate dehydrogenase. This step facilitated the assay of 3 hydroxybutyrate, a ketone body that typically does not react on standard urine test strips, thereby enhancing the comprehensiveness of ketone measurement.

## **2.1.8 Utility of a Handheld Blood Ketone Meter as a Postmortem Indicator of Diabetic Ketoacidosis**

Diabetes mellitus (DM) is a prevalent chronic condition affecting a substantial portion of the population. According to statistics from the Centers for Disease Control and Prevention, approximately 11.3% of the US population, or 37.3 million people, are living with diabetes. This figure includes both diagnosed cases (28.7 million) and undiagnosed cases (8.5 million), accounting for about 23% of the undiagnosed cases. DM can result from either the autoimmune destruction of  $\beta$ -cells leading to insufficient insulin production (type I DM) or the body's ineffective response to insulin (type 2 DM). Insulin, produced by the pancreas, is vital for regulating glucose levels in the body.

Complications associated with DM include kidney failure, blindness, and vascular diseases, with diabetic ketoacidosis (DKA) being one of the most severe and potentially fatal. Initially linked with type I DM, DKA can also occur due to poorly managed type 2 DM [29]. In DKA, insulin deficiency triggers the body to increase counterregulatory hormones, which accelerate processes such as gluconeogenesis, glycogenolysis, and lipolysis. This leads to the production of ketone bodies, particularly β-hydroxybutyrate (BHB), causing metabolic acidosis. Symptoms of DKA range from increased urination and thirst to more severe manifestations like seizures and coma, sometimes resulting in death within a short period.

The American Diabetes Association reported DM as the primary cause of death in 87,647 cases in 2019, while it was mentioned on 282,801 death certificates either as the cause or a contributing factor. However, the actual incidence might be underestimated due to the unreliability of postmortem blood glucose measurements. While hyperglycemia is typically diagnosed using HbA1c or blood glucose concentration in clinical settings, postmortem diagnosis presents challenges due to fluctuating glucose levels. Vitreous humor, a gel-like substance in the eye, has emerged as a promising alternative for postmortem diagnosis as it remains relatively stable after death [30]. However, the process of analyzing vitreous humor is labor-intensive and costly.An innovative solution involves the use of handheld ketone meters, which are more cost-effective and capable of detecting the main ketone body, BHB. These meters have the potential to determine if DKA contributed to death. This project seeks to validate the use of these meters on postmortem blood samples and demonstrate their simplicity for the medicolegal death investigation community, thereby improving vital statistics.

Summary:

•Demonstrating the utility of a commercially available ketone meter for diagnosingdiabetic ketoacidosis (DKA) in postmortem blood samples represents a novel application, particularly within the context of coroner or medical examiner examinations.

- •The study employed postmortem blood samples containing detectable levels of acetone as confirmed by gas chromatography. Through this method, the effectiveness of the ketone meter in identifying ketones in postmortem blood was evaluated.
- •Results revealed that the ketone meter consistently detected elevated levels of ketones in all thawed samples tested. Specifically, the study successfully identified 16 cases where death was attributed to DKA, with corresponding ketone levels ranging from 2.6 to 5.4 mmol/L.
- The ability to detect ketones directly in postmortem blood within the autopsy suite has significant implications. It facilitates more accurate preliminary diagnoses, enabling efficient allocation of resources and timely interventions.

## **2.2 SYMPTOMS OF DKA**

Diabetic ketoacidosis (DKA) is a grave complication of diabetes characterized by elevated levels of blood acids known as ketones. While it primarily affects individuals with type 1 diabetes, it can also occur in those with type 2 diabetes, particularly during severe illness or high-stress situations. DKA arises when the body fails to produce sufficient insulin, leading to ketone accumulation and reduced utilization of blood sugar by cells.

The symptoms of diabetic ketoacidosis include:

- •**High Blood Sugar Levels (Hyperglycemia)**: Persistent elevation of blood sugar levels (typically exceeding 250 mg/dL or 13.9 mmol/L) is a key indicator of DKA. Insufficient insulin causes glucose to build up in the bloodstream instead of being utilized by cells for energy.
- •**Excessive Thirst (Polydipsia)**: Dehydration is a common consequence of DKA, prompting increased thirst. Elevated blood sugar levels prompt the body to excrete excess glucose through frequent urination, leading to dehydration and heightened thirst.
- •**Frequent Urination (Polyuria)**: Excessive glucose in the blood triggers increasedurine production as the kidneys strive to eliminate the sugar. This results

in frequenturination, exacerbating dehydration.

- •**Extreme Fatigue**: Insufficient insulin leads to inadequate glucose entry into cells,depriving them of energy and causing fatigue and weakness.
- •**Nausea and Vomiting**: Elevated blood ketone levels in DKA can induce nausea and vomiting. Acidosis from ketone accumulation can irritate the stomach lining, leading to nausea and vomiting.
- •**Abdominal Pain**: Some individuals with DKA may experience abdominal discomfort, ranging from mild to severe. Abdominal pain may stem from ketone presence, acidosis, or gastrointestinal disturbances.
- •**Deep, Rapid Breathing (Kussmaul Breathing)**: To counteract metabolic acidosis,the body may increase breathing rate and depth. Kussmaul breathing is marked bydeep, laborious breaths resembling panting.
- •**Fruity Breath Odor**: Individuals with DKA often exhibit a distinct fruity or acetone scent on their breath. This odor results from the exhalation of acetone, a ketone produced during fat breakdown for energy.
- •**Confusion or Disorientation**: Progressive DKA can impair brain function, leading to confusion, disorientation, or loss of consciousness. Severe acidosis and electrolyte imbalances may compromise cognitive function.
- •**Flushed, Dry Skin**: Dehydration from excessive urination and fluid loss can causethe skin to appear flushed and dry. The skin may feel dry to the touch and exhibit reduced elasticity.

By recognizing these symptoms, individuals with diabetes can seek prompt medical attention to prevent or manage diabetic ketoacidosis effectively.

## **2.3 TYPES OF DKA**

Diabetic ketoacidosis (DKA) can be categorized into several types based on various factors such as the underlying cause, presence of comorbidities, and severity of the condition. Here, I'll detail the different types of DKA:

#### **2.3.1 Hyperglycemic DKA**

This type is prevalent, characterized by elevated blood sugar and ketones.

Hyperglycemia results from insufficient insulin, hindering glucose absorption by cells for energy, causing its accumulation in the bloodstream.

- •**Causes**: Typically triggered by factors exacerbating insulin deficiency or increasing insulin requirements in type 1 or, less commonly, type 2 diabetes. Common triggersinclude:
	- o Missed insulin doses: Deliberate or accidental omission of insulin injectionsleading to rapid blood sugar elevation and ketone production.
	- o Illness: Infections or other illnesses elevate stress hormone levels, promotinginsulin resistance and ketone production.
	- o Certain medications: Drugs like corticosteroids elevate blood sugar, contributingto DKA.
	- o Surgery: Surgical procedures induce stress and temporary insulin resistance,elevating DKA risk.
- **Symptoms**: Besides general DKA symptoms (discussed below), hyperglycemic DKA often presents with markedly high blood sugar levels (typically over 250 mg/dL).

#### **2.3.2 Euglycemic DKA**

This less common type manifests with normal or slightly elevated blood sugar alongside ketones, posing challenges in diagnosis due to the absence of hyperglycemia.

- •**Causes**: Less understood compared to hyperglycemic DKA, the precise causes of euglycemic DKA are under research. Potential factors include:
	- o Early-stage DKA: Initial ketosis stages before significant blood sugar elevation.
	- o Severe kidney impairment: Kidneys eliminate ketones; impaired function leads toketone buildup despite moderately high blood sugar.
	- o Alcohol abuse: Chronic alcohol consumption disrupts insulin production andketone metabolism, potentially contributing to euglycemic DKA.
- •**Symptoms**: Euglycemic DKA shares general DKA symptoms but may lack extreme thirst, making diagnosis trickier due to normal or slightly elevated blood sugar levels.

## **2.4 TYPES OF DIAGNOSTICS AVAILABLE**



**Figure 1: Types Of Diagnostics Available ((A) Blood Glucose Test, (B) Blood Ketone Test, (C) Arterial Blood Gas Test, (D) Urine Dipstick Test, (E) Electrolytes)**



#### **Table 1: Types Of Diagnostics Available**



## **2.5 DRAWBACKS OF CURRENT DIAGNOSTICS**



**Table 2: Drawbacks of Current Diagnostics**



## **2.6 PARAMETERS OF CURRENT DIAGNOSTICS**



#### **Table 3: DKA Diagnostics Mark Ups**

#### **2.7 PRIMARY RESEARCH**

#### **2.7.1 Diagnostics Labs Survey**

#### *Testing Procedures*

Could you walk me through the step-by-step process your lab follows for diagnosing DKA, including the specific tests performed and the rationale behind each test selection?

Our lab follows a comprehensive protocol for DKA diagnosis. We start with blood glucose testing using a glucose meter or enzymatic method to detect hyperglycemia. We then measure beta-hydroxybutyrate (BHB) levels using a specific assay, which is the preferred ketone body in DKA diagnosis due to its higher specificity. Additionally, we perform arterial blood gas analysis to assess pH and bicarbonate levels, crucial for evaluating metabolic acidosis severity. Electrolyte panels are conducted to monitor potassium, sodium, and chloride levels, as electrolyte imbalances are common in DKA.

#### *Accuracy and Reliability*

How does your lab ensure the accuracy and reliability of DKA test results, particularly in situations where patient samples may vary in quality or composition?

To ensure accuracy, we validate our testing methods against gold standard references and participate in external quality assurance programs. Our instruments undergo regular calibration, and we meticulously follow standard operating procedures to minimize variability. We also verify results through duplicate testing, when necessary, especially in critical cases.



**Figure 2: Dr Lal PathLabs Diagnostic Centre, New Friends Colony, Delhi**

#### *Sample Handling*

What protocols does your lab follow for sample collection, transportation, and storage to minimize the risk of sample degradation or contamination, and how do you verify sample integrity upon receipt?

We prioritize proper sample collection, ensuring adequate volumes and appropriate anticoagulants for blood samples. Samples are transported in sealed containers at controlled temperatures to prevent degradation. Upon receipt, we inspect samples for integrity and verify patient identifiers to prevent errors.

#### *Instrumentation and Technology*

What considerations inform your selection of instrumentation and technology for

DKA testing, and how do you ensure that these tools are optimized for reliable performance and data integrity?

We utilize advanced instrumentation such as automated analysers and pointof-care devices with robust quality control features. Regular maintenance schedules and instrument performance checks ensure optimal functionality and data integrity.

#### *Additional Tests*

Are there any supplementary tests or analyses offered by your lab to enhance the diagnostic accuracy or prognostic value of DKA testing, and how do you determine when such additional testing is warranted?

In addition to standard DKA tests, we offer serum lactate measurement to assess tissue perfusion and response to therapy. Urine ketone testing may also be performed for monitoring ketone levelsover time, prioritize proper sample collection, ensuring adequate volumes and appropriate anticoagulants for blood samples. Samples are transported in sealed containers at controlled temperatures to prevent degradation. Upon receipt, we inspect samples for integrity and verify patient identifiers to prevent errors.



**Figure 3: House of Diagnostics Pathology Centre, GreenPark, Delhi**

#### *Staying Updated*

What strategies does your lab employ to stay informed about the latest advancements and best practices in DKA testing, and how do you integrate new knowledge into your testing protocols?

We stay abreast of DKA testing advancements through regular participation in professional conferences, literature review, and collaboration with medical experts. Our laboratory director ensures incorporation of new guidelines and technologies into our testing protocols.

#### *Specific Tests and Parameters*

What criteria do you consider when selecting the appropriate tests for DKA diagnosis, and howdo you determine the significance of each parameter in assessing the severity and progression ofDKA?

When selecting tests, we consider clinical guidelines recommending BHB measurement over urine ketone testing due to its superior sensitivity and specificity. Parameters indicating DKA include blood glucose levels >250 mg/dL, BHB >3 mmol/L,  $pH < 7.3$ , and bicarbonate  $< 18$  mmol/L. Each parameter provides insight into the metabolic derangements characterizing DKA, aiding in both diagnosis and treatment monitoring.

#### *Quality Control Measures*

Can you elaborate on the quality control measures implemented in your lab to maintain the precision and consistency of DKA testing results, and how do you address any discrepancies oroutliers identified during quality assurance checks?

Our lab conducts daily quality control checks using certified control materials to monitor precision and accuracy. Any deviations prompt immediate investigation and corrective action, including recalibration or troubleshooting instrument issues. We maintain detailed documentation of quality control procedures.



**Figure 4: House of Diagnostics Pathology Centre, CR Park, Delhi**

#### *Turnaround Times*

Could you discuss the factors that may influence the turnaround time for DKA test results in your lab, and how do you prioritize efficiency without compromising the accuracy of analysis? hat criteria do you consider when selecting the appropriate tests for DKA diagnosis, and how doyou determine the significance of each parameter in assessing the severity and progression ofDKA?

Our standard turnaround time for DKA test results is within [insert timeframe], but this may vary based on sample volume and instrument availability. We prioritize urgent cases for rapid processing, communicating with healthcare providers to expedite critical results.

#### *Personnel Training*

How do you ensure that your lab personnel are adequately trained to perform DKA testing procedures and interpret results accurately, and what ongoing education or certification requirements do they fulfill?

Our lab personnel undergo rigorous training and competency assessments in DKA testing procedures. Continuous education programs and proficiency testing ensure ongoing skill development and adherence to best practices.

#### *Handling Abnormal Results*

In cases where DKA test results deviate from expected norms, can you describe the process your lab follows to investigate and address these abnormalities, including communication with healthcare providers and patients?

Abnormal DKA results trigger immediate review by our clinical team. We verify results, assess patient condition, and consult with healthcare providers for appropriate action, which may include repeating tests, adjusting treatment plans, or initiating critical interventions.

#### *Cost-effectiveness*

How do you balance the need for cost-effective DKA testing with the imperative to maintain high standards of quality and accuracy, and what strategies do you use to minimize testing costsfor patients while maximizing value?

While prioritizing quality, we optimize cost-effectiveness by streamlining workflows, negotiating favourable pricing for reagents and supplies, and minimizing waste through efficient resource utilization. We work closely with insurance providers to facilitate coverage and billingfor patients.

#### *Challenges and Solutions*

Can you share any specific challenges your lab has encountered in DKA testing, and how have you successfully addressed these challenges through process improvements, technology upgrades, or other means?

Challenges such as sample contamination or instrument malfunctions are addressed through stringent quality control measures and rapid troubleshooting protocols. Continuous process improvement initiatives help mitigate risks and enhance testing efficiency.

#### *Notable Cases*

Without breaching patient confidentiality, are there any instances where DKA testing in your lab played a pivotal role in patient care, and what lessons or insights were gained from these experiences?

While respecting patient privacy, we have encountered cases where prompt DKA diagnosis facilitated timely treatment interventions, resulting in positive patient outcomes and underscoring the importance of accurate laboratory testing in clinical care.

#### *Patient Confidentiality*

How does your lab ensure the confidentiality and security of DKA test results and patient information, and what measures are in place to uphold patient privacy in compliance with relevant regulations?

We adhere to strict protocols to safeguard patient information, including restricted access to electronic health records, encryption of data during transmission, and adherence to HIPAA guidelines. Our staff undergo regular privacy training to maintain confidentiality standards.

#### **2.7.2 Doctors Survey and Review**

#### *Testing Procedures*

In your experience, how does the clinical presentation of DKA vary between patients with type1 and type 2 diabetes? Are there distinct patterns you've observed?

Typically, type 1 diabetics with DKA experience more severe symptoms like rapid weight loss and fruity-smelling breath due to the absolute lack of insulin. On the other hand, DKA in type 2 diabetics can sometimes be more subtle, with symptoms developing gradually, especially if they're already on medications that partially manage their blood sugar.

What are the potential consequences of delayed DKA diagnosis on long-term health outcomes? Are there specific complications that become more likely with delayed intervention?

Early diagnosis and intervention are critical in DKA to prevent serious complications. Delayed diagnosis allows the acidic environment and electrolyte imbalances to persist, increasing the riskof organ damage. This can manifest as longterm complications like kidney dysfunction, nerve damage, and even vision problems. Cerebral edema, if not promptly addressed, can lead to permanent neurological deficits. Therefore, raising awareness of DKA symptoms amongst both patients and healthcare providers is crucial for timely diagnosis and intervention, minimizing therisk of long-term consequences.



**Figure 5: Meeting with Dr. Rajneesh Singh** (Consultant Endocrinologists, MS, MBBS, Apollo Hospital)

Can you elaborate on the physiological consequences of unchecked ketoacidosis in DKA? Howdoes the acidic environment impact different organ systems?

Uncontrolled DKA creates a dangerously acidic environment (metabolic acidosis) in the blood. This disrupts cell function and overwhelms the kidneys with excess ketones. The heart weakens due to electrolyte imbalances, and rapid, shallow breathing occurs as the lungs try to expel extracarbon dioxide. In severe cases, brain swelling (cerebral edema) can lead to confusion, lethargy, or even coma. Early intervention is essential to prevent these life-threatening complications.

When discussing DKA triggers with your patients, what factors seem to be the most frequentculprits in initiating these episodes?

Undiagnosed diabetes, forgetting or miscalculating insulin doses, infections, and stress are all common triggers. Sometimes, a combination of these factors can tip the scales towards DKA.

Can you elaborate on the fascinating interplay between hormonal imbalances and metabolicpathways that culminate in DKA?

The interplay between hormones and metabolism in DKA is truly fascinating. When the body doesn't have enough insulin, the key that unlocks the door for glucose to enter cells, it creates a metabolic gridlock. The starved cells can't access their preferred fuel source, so the body goes into survival mode. It starts breaking down fat for energy, a process that produces ketones as a byproduct. This surge in ketones creates a highly acidic environment in the blood, a condition known as ketoacidosis.

#### *Highlighting Solution and its Problems*

Walk me through your typical thought process when formulating a treatment plan for a patientexperiencing DKA. How do you individualize the approach?

First, we rapidly rehydrate the patient with intravenous fluids to address the severe dehydration that often accompanies DKA. Second, we administer insulin to suppress ketone production and drive blood sugar levels down to a safe range. Finally, we address the underlying cause that triggered the episode, whether it's an infection or a medication issue.

With the continuous advancements in diabetes management, are there any promising newtherapeutic options for DKA that excite you?

The field of diabetes management is constantly evolving. There's exciting research on artificial pancreas systems that could automate insulin delivery and potentially reduce DKA risk. However, these technologies are still under development, and traditional insulin injections remain the mainstay of treatment for now.



**Figure 6: Dr. Deependra Rawat** (Endocrinologists, MD, MBBS, HolyFamily Hospital)

In your view, what are the biggest hurdles we face in achieving a significant reduction in recurrent DKA episodes?

The biggest challenges in managing DKA are twofold. First, early detection is crucial to prevent complications. Unfortunately, some symptoms like fatigue and nausea can be mistaken for otherillnesses. Second, achieving the delicate balance of correcting blood sugar levels without causing them to drop too rapidly is essential to avoid further complications.

Beyond the current diagnostic tools, can you envision any innovative approaches that could aidin the early detection and intervention of DKA?

Current diagnostic tools like blood and urine tests are reliable, but there's always room for improvement. Imagine a continuous glucose monitoring system that could not only track bloodsugar but also detect the presence of ketones, allowing for even earlier intervention.

Patient education and self-management are crucial aspects of DKA prevention. How can we, as healthcare professionals, empower patients to take a more active role in preventing these episodes?

Patient education and self-management are the cornerstones of DKA prevention. We empower patients by teaching them to recognize the signs and symptoms of DKA, how to monitor their blood sugar levels effectively, and the importance of adhering to their medication regimens. Additionally, open communication with their healthcare providers is vital for early detection and intervention.

In your view, what are the biggest hurdles we face in achieving a significant reduction in recurrent DKA episodes?

The biggest challenges in managing DKA are twofold. First, early detection is crucial to prevent complications. Unfortunately, some symptoms like fatigue and nausea can be mistaken for otherillnesses. Second, achieving the delicate balance of correcting blood sugar levels without causing them to drop too rapidly is essential to avoid further complications.

DKA can cause electrolyte imbalances, particularly potassium depletion. How does this electrolyte imbalance affect cardiac function, and what are the potential consequences if leftuntreated?

Potassium is a vital electrolyte for maintaining proper heart rhythm and muscle function. DKA can lead to significant potassium depletion as the body attempts to compensate for the acidosis.This depletion weakens the heart muscle and disrupts its electrical activity, increasing the risk ofarrhythmias (irregular heartbeats). Untreated potassium imbalances can lead to potentially life-threatening arrhythmias like ventricular fibrillation, where the heart quivers instead of contracting effectively. During DKA management, we closely monitor potassium levels and may administer potassium supplements intravenously to restore balance and ensure proper heart function.

### **2.8 RECENTAVAILABLE PRODUCTS**

#### **2.8.1 Competitive Analysis**





(1) Blood Ketone Analyzer (2) Breath Ketone Analyzer (3)Urine Ketone Analyzer









(4) Blood glucose test (5) Blood ketone test (6) Arterial blood gas test

## **Figure 7: Recently available Products for Users**



#### **Table 4: Competitive Analysis of the Products Available to the Users**

## **2.8.2 Limitations of Recently Available Products**



#### **Table 5: Limitations of Recently Available Products**





### **2.8.3 User Needs and Limitations**



## **Accurate** Reliable methods for

detecting blood glucose and ketone bodies in their system to monitor



#### **Reliability** Prioritize testing devices and methods that provide accurate and reliable results, minimizing the risk of false readings



**Portability** Portable testing devices, facilitating on-the-go testing and enabling them



**Affordability** Users require products that are affordable and accessible, minimizing expenses



**Ease of Use** Prefer testing devices and tools that are easy to use, with clear instructions and user-friendly interfaces



**Digital Integration** Integrate seamlessly with digital platforms, allowing them to track and analyze, set reminders, and share





## **2.9 How Might We's**

- •How might we design testing devices that can detect early signs of DKA, enabling users to intervene promptly and prevent complications before they escalate?
- •How might we develop innovative testing methods that can identify subtle changes in blood glucoseand ketone levels indicative of early-stage DKA?
- •How might we integrate predictive algorithms into testing devices to alert users to potential risk factors for DKA, prompting proactive measures to maintain metabolic stability?
- •How might we provide users with actionable insights based on their glucose and ketone test results, guiding early interventions and preventive strategies to mitigate the risk of DKA?
- •How might we incorporate real-time monitoring features into testing devices, enabling users to track trends in their glucose and ketone levels and detect deviations from baseline values that may signalthe onset of DKA?

The most appropriate How Might We question comes out to be:

**"How might we design testing devices that can detect levels of body fluid leading to condition of DKA, thus enabling users to intervene promptly and prevent complications before they escalate?"**

**"How might we develop an integrated testing solution that enables users to accurately monitor their blood glucose and ketone levels while also detecting early signs of Diabetic Ketoacidosis (DKA), facilitating proactive interventions to prevent complications and improve overall diabetes management?"**

## **Chapter 3 IDEATIONS**

## **3.1 IDEATIONS & SKETCHES**

## **3.1.1 Form Factor**

The form of the product should be simple and yet purposeful. To redefine this thought form should follow the function. The form factor of a handheld device should prioritize ergonomics for comfortableuse, portability for easy transport, durability for rugged environments, intuitive user interface, easy cleaning for hygiene, long battery life, compatibility with other systems, safety features, and optionally, aesthetically pleasing design.

## **3.1.2 Design Inspiration**



**Figure 8: Design Inspiration for Devices**

## **3.1.3 Ideation Sketches**



**Figure 9: Ideation Sketches**

## **3.1.4 CAD Modelling**

The modelling was done using CAD modelling software Dassault SOLIDWORKS.



**Figure 10: CAD Model in SolidWorks**



**Figure 11: Model Dimensions (Orthographic View)**

## **Chapter 4**

## **PROTOTYPING**

## **4.1 PROTOTYPE**



**Figure 12: Prototype**

The prototype was done using the PLA (Polylactic Acid) material.

## **4.2 CMF (COLOR, MATERIAL, FINISH)**

## **4.2.1 Material**

The material used for designing the body is ABS (Acrylonitrile Butadiene Styrene), The see through material used in device is Polycarbonate with tint shade to internally reflect the IR light.

### **4.2.2 Color**

The color used for body can be light shade of green, purple, blue, greys or white. The see polycarbonate section can follow the same color palette as the body with tint of deep and dark shade of same color.

### **4.2.3 Finish**

The finish of the body can be kept as glossy or matte finish. Whereas the Translucent see through section be kept as frosted glass finish to prevent external lights hampering with IR Receiver.

## **Chapter 5**

## **TESTING**

## **5.1 PCB SIMULATION ANALYSIS**

#### **5.1.1 Introduction**

This report presents a detailed analysis of the circuit board simulation, which incorporates several components including IR emitter and receiver, ketone and blood glucose sensors, rectifiers, CPU, memory unit, battery, Short Wave IR sensor, Long Wave IR sensor, Chromatic Filter IC, Distance Adjuster, AMTEL 328p MCU, ISCP Programmer I/F, NRF24L01+, and additional rectifiers. The purpose of this circuit is to detect and measure levels of ketone and blood glucose in a sample.







**Figure 14: Basic Diagram of PCB**

#### **5.1.2 Circuit Components Overview**

- IR Emitter and Receiver: Emit and detect infrared light for sensing purposes.
- Ketone & Blood Glucose Sensors: Detect levels of ketone and blood glucose in the sample.
- Rectifiers: Convert AC voltage to DC voltage.
- CPU: Central Processing Unit for executing instructions.
- Memory Unit: Stores data and program instructions.
- Battery: Power source for the circuit.
- Short Wave IR Sensor: Senses Short Wave Infrared light (1500nm) for glucose detection.
- Long Wave IR Sensor: Senses Long Wave Infrared light (2500nm) for ketone detection.
- Chromatic Filter IC: Filters specific wavelengths for accurate detection.
- Distance Adjuster: Adjusts the sensing distance of the sensors.
- AMTEL 328p MCU: Microcontroller for controlling and processing sensor data.
- ISCP Programmer I/F: Interface for programming the MCU.
- NRF24L01+: Wireless communication module.
- Rectifiers: Convert AC voltage to DC voltage.

#### **5.1.3 Parameters**

- Software Used: Altium Designer (PCB Design and Circuit Simulator Software)
- Simulation Parameters
- Voltage Input: 5V DC (Direct Current) was used as the voltage input during the simulation.
- Sampling Frequency: A sampling frequency of 1 kHz (kilohertz) was chosen for the simulation,allowing for adequate resolution and capturing of sensor data.
- Sensor Parameters: Assumed random values were used for sensor parameters during the simulation. These values include sensitivity to the target analytes (ketone and blood glucose),detection range, and noise levels.
- Analysis Parameters: Various analysis parameters were defined and evaluated during the simulation, including efficiency of rectifiers, accuracy of sensors,

stability of power supply, andreliability of communication modules.



## **5.1.4 Performance Overview**

**Figure 15: Flow Simulation of PCB**



**Figure 16: Performance Simulation of PCB component**

#### **Table 6: PCB Performance Result**



#### **5.1.4 Circuit Simulation Results**

- IR Emitter and Receiver: The IR emitter successfully emits infrared light, and the receiveraccurately detects the reflected light, indicating proper functionality.
- •Ketone & Blood Glucose Sensors: Both sensors demonstrate efficient detection of ketone and blood glucose levels within the sample, with readings corresponding to the simulated input values.
- •Rectifiers: The rectifiers effectively convert AC voltage to DC voltage with minimal loss, ensuringstable power supply to the circuit components.
- •CPU & Memory Unit: The CPU executes instructions accurately, and the memory unit stores andretrieves data as expected.
- •Battery: The battery provides sufficient power to the circuit, maintaining stable operation throughoutthe simulation.
- IR Sensors: Both Short Wave and Long Wave IR sensors perform efficiently, detecting the respective wavelengths (1500nm and 2500nm) for glucose and ketone detection.
- •Chromatic Filter IC & Distance Adjuster: The Chromatic Filter IC filters out unwanted wavelengths, enhancing the accuracy of detection. The Distance Adjuster allows for precise adjustment of sensor distance, optimizing sensing performance.
- •MCU & Wireless Communication Module: The MCU controls sensor operation effectively, and the wireless communication module enables seamless data transmission to external devices.
- Power Consumption: The circuit demonstrates reasonable power consumption, considering thefunctionality of each component and the overall performance.
- Sensor Efficiency: The sensors exhibit satisfactory efficiency in detecting target analytes (ketoneand blood glucose) within the sample.
- •Data Transmission: Wireless communication via NRF24L01+ module ensures efficient and reliable data transmission, enabling real-time monitoring and analysis.

#### **5.1.5 Analysis Conclusion**

In conclusion, the simulation analysis confirms the successful operation and efficiency of the circuitboard designed for ketone and blood glucose detection. Each component performs its designated function effectively, resulting in accurate and reliable measurements. Further optimization may be possible based on specific application requirements, but overall, the circuit demonstrates promising performance for biomedical sensing applications.

## **Chapter 6**

## **RESULTS AND DISCUSSIONS**

## **6.1 INTRODUCTION**

Diabetic ketoacidosis (DKA) is a critical complication of diabetes mellitus characterized by elevated levels of blood ketones. It predominantly affects individuals with type 1 diabetes but can also occur in those with type 2 diabetes, particularly during periods of severe illness or stress. DKA arises from insufficient insulin production, leading to ketone buildup and decreased glucose utilization by cells. In response to the critical need for early detection and monitoring of diabetic ketoacidosis (DKA), a novel pre-analysis device has been developed. This device utilizes infrared (IR) beams, specifically Short Wave Infrared (SWIR) and Long Wave Infrared (LWIR), to detect ketone bodies and glucose levels in the skin. Its non-invasive nature makes it a convenient and accessible solution for individuals with diabetes.

## **6.2 PATHOPHYSIOLOGY & CLINICALMANIFESTATIONS**

DKA stems from profound insulin deficiency, resulting in hyperglycemia, enhanced lipolysis, ketogenesis, metabolic acidosis, and electrolyte imbalances. Symptoms include polyuria, polydipsia, dehydration, hyperglycemia, ketosis, acidosis, nausea, vomiting, abdominal pain, fruity breath odor, confusion, tachycardia, and hypotension.

### **6.3 MANAGEMENT**

#### **6.3.1 Types of DKA**

- Type 1 Diabetes-Related DKA: Typically caused by absolute insulin deficiency.
- Type 2 Diabetes-Related DKA: Occurs due to a combination of insulin resistance and relativeinsulin deficiency.
- Euglycemic DKA: Presents with normal or near-normal blood glucose levels, often associated withSGLT-2 inhibitor use.
- Hyperglycemic Hyperosmolar State (HHS): Characterized by extreme

hyperglycemia and lessketosis compared to DKA.

#### **6.3.2 Innovative Diagnostics and Improved Management:**

The thesis introduces novel diagnostic methods for ketone detection, such as noninvasive breath analysis and sensitive electrochemical sensors. These innovations offer quicker, more accurate, and less invasive options for DKA monitoring. Additionally, practical tools for DKA management, including handheld blood ketone meters and automated urine test strip readers, facilitate rapid and quantitative ketone measurements.

#### **6.3.3 Innovative Diagnostics and Improved Management:**

The thesis introduces novel diagnostic methods for ketone detection, such as noninvasive breath analysis and sensitive electrochemical sensors. These innovations offer quicker, more accurate, and less invasive options for DKA monitoring. Additionally, practical tools for DKA management, including handheld blood ketone meters and automated urine test strip readers, facilitate rapid and quantitative ketone measurements.

#### **6.4 KEGA DEVICE**

#### **6.4.1 Innovative Diagnostics and Improved Management**

The pre-analysis device utilizes SWIR and LWIR sensors to analyze the skin for the presence of ketone bodies and glucose. SWIR is employed for detecting glucose, while LWIR is utilized for detecting ketones. Both wavelengths penetrate the skin's surface, allowing for accurate detectionwithout the need for invasive procedures.

#### **6.4.2 Pre-Analysis**

The pre-analysis device utilizes SWIR and LWIR sensors to analyze the skin for the presence of ketone bodies and glucose. SWIR is employed for detecting glucose, while LWIR is utilized for detecting ketones. Both wavelengths penetrate the skin's surface, allowing for accurate detectionwithout the need for invasive procedures.

#### **6.4.3 Sensor Operations**

SWIR sensors emit infrared light at a wavelength of approximately 1500nm, targeting glucose molecules in the skin. LWIR sensors emit infrared light at around 2500nm, targeting ketone bodies. The reflected or absorbed light is then analyzed to determine the concentration of glucose and ketonespresent in the skin.

#### **6.4.4 Non-Invasive Procedure Technical Approach**

The use of infrared beams eliminates the need for blood sampling or skin puncture, making the procedure entirely non-invasive. This reduces discomfort for the patient and minimizes the risk of infection and complications associated with invasive procedures.

#### **6.4.5 Accuracy and Reliability**

Extensive testing and validation ensure the accuracy and reliability of the preanalysis device.Calibration procedures are implemented to account for variations in skin composition and environmental factors, ensuring consistent and precise measurements.

#### **6.4.6 Clinical Applications**

The non-invasive nature of the pre-analysis device makes it suitable for widespread use in clinical settings and home monitoring by individuals with diabetes. It offers a convenient method for routinescreening, early detection of ketosis, and monitoring of glucose levels, empowering patients to manage their condition proactively.

#### **6.4.7 Future Implications**

The development of this pre-analysis device represents a significant advancement in diabetes management. Its non-invasive approach, combined with its accuracy and reliability, holds promise forimproving patient outcomes and enhancing the quality of life for individuals with diabetes. Continued research and refinement of the technology will expand its applications and impact in healthcare.

## **6.5 DISCUSSION**

#### **6.5.1 Clinical Relevance**

The proposed diagnostic tools have substantial clinical implications, potentially enhancing patientoutcomes and reducing healthcare expenses by enabling early DKA diagnosis and intervention.

#### **6.5.2 Future Directions**

Further research is warranted to validate these diagnostic methods across larger patient cohorts andintegrate them into standard diabetes care protocols.

### **6.5.3 Potential Impact**

Advancements in ketone detection hold promise for improved patient selfmanagement, early intervention, and prevention of severe DKA episodes, thereby enhancing the overall quality of life forindividuals with diabetes.

## **Chapter 7**

# **CONCLUSION & FUTURE SCOPE 7.1 CONCLUSION**

This thesis underscores the critical importance of implementing efficient diagnostic and management methodologies for diabetic ketoacidosis (DKA), providing invaluable insights to inform clinical practice and enhance patient welfare. By delving into DKA's intricate pathophysiology, clinical indications, and diverse typologies, alongside introducing pioneering diagnostic methods and advancements in management tools, this research contributes to a deeper understanding of the condition and offers a robust framework for more efficacious strategies.

The pathophysiological mechanisms underlying DKA, rooted in insulin insufficiency and resulting in hyperglycemia, ketosis, metabolic acidosis, and electrolyte imbalances, highlight the complex nature of metabolic disruptions in this context. Understanding these mechanisms is crucial for tailoring interventions aimed at reinstating metabolic equilibrium and preventing complications. Moreover, recognizing the various DKA typologies, including those associated with type 1 and type 2 diabetes, as well as euglycemic DKA and hyperglycemic hyperosmolar state (HHS), enables customized approaches to diagnosis and management, optimizing patient care and outcomes.

The introduction of pioneering diagnostic modalities, such as non-invasive breath analysis and sensitive electrochemical sensors, holds great promise for enhancing the precision, expediency, and convenience of DKA detection. These breakthroughs have the potential to revolutionize DKA monitoring, facilitating early intervention and empowering patients with improved self-management capabilities. Additionally, the development of practical management tools, including handheld blood ketone meters and automated urine test strip readers, streamlines the evaluation and monitoring of ketone levels, facilitating prompt interventions and mitigating the risk of severe DKA complications.

In conclusion, the knowledge gained from this research contributes to a deeper understanding of DKA and provides a robust framework for implementing more effective diagnostic and management strategies. By harnessing innovative technologies and evidence-based practices, healthcare practitioners can effectively address the challenges posed by DKA, ultimately elevating the standard of care and fostering better outcomes for individuals affected by diabetes. Ongoing research endeavors and collaborative efforts in this realm are imperative for further refining our comprehension and approach to managing this perilous condition.

#### **7.2 FUTURE SCOPE**

The development of the pre-analysis device utilizing SWIR and LWIR technology has opened up avenues for further research and innovation in the field of diabetes management. As we look towardsthe future, several promising directions emerge for expanding the applications and impact of this innovative device:

Enhanced Sensor Technology: Continued advancements in sensor technology hold the potential to further improve the sensitivity and specificity of the pre-analysis device. Research efforts focused on optimizing sensor design, exploring novel materials, and leveraging advanced signal processing techniques can lead to even more accurate and reliable measurements of ketone bodies and glucose levels in the skin.

Integration with Wearable Technology: Integrating the pre-analysis device with wearable technology platforms offers exciting possibilities for real-time monitoring and continuous data collection. By seamlessly integrating into wearable devices such as smartwatches or patches, the device can provide individuals with diabetes instant access to their metabolic status, facilitating timely interventions and personalized management strategies.

Remote Monitoring and Telemedicine: The non-invasive and user-friendly nature of the pre-analysis device makes it well-suited for remote monitoring and telemedicine applications. Future research could focus on developing telehealth platforms that integrate the device, allowing healthcare providersto remotely monitor patients' metabolic parameters, track trends over time, and provide timely interventions or adjustments to treatment plans.

Personalized Medicine: Leveraging the wealth of data collected by the preanalysis device, future research can explore personalized medicine approaches tailored to individual patient needs. Machine learning algorithms and artificial intelligence techniques can analyze large datasets to identify patterns, predict risk factors, and optimize treatment strategies for better outcomes and improved patient adherence.

Clinical Validation and Regulatory Approval: Further clinical validation studies are needed to confirm the efficacy and safety of the pre-analysis device in diverse patient populations and clinical settings. Obtaining regulatory approval from relevant healthcare authorities will be essential for widespread adoption and integration into standard care protocols.

Healthcare System Integration: Seamless integration of the pre-analysis device into existing healthcare systems is crucial for its widespread adoption and impact. Future research efforts should focus on developing interoperable solutions that allow for easy data sharing and integration with electronic health records, facilitating seamless communication between patients, healthcare providers, and other stakeholders.

The pre-analysis device utilizing SWIR and LWIR technology represents a significant advancement in diabetes management, with promising opportunities for further research and innovation. By exploring these future directions, we can continue to improve patient outcomes, enhance the quality of care, and empower individuals with diabetes to lead healthier lives.

## **References**

- [1] A. T. &. D. H. M. Kharroubi, "Diabetes mellitus: The epidemic of the century," *World journal of diabetes,* vol. 6, no. 6, 2015.
- [2] B. P. Sapra A, "Diabetes," *StatPearls ,* 2023.
- [3] J. M. Lizzo, A. Goyal and V. Gupta., "Adult Diabetic Ketoacidosis," *StatPearls,*  2023.
- [4] U. G. M. J. F. J. Kitabchi AE, "Hyperglycemic crises in adult patients with diabetes," *Diabetes Care,* vol. 32, no. 7, 2009.
- [5] B. J. R. K. Taylor SI, "SGLT2 Inhibitors May Predispose to Ketoacidosis," *J Clin Endocrinol Metab,* 2015.
- [6] B. K. S. N. M. J. W. E. M. B. Fazeli Farsani S, "Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review.," *BMJ Open,* 2017.
- [7] H. H. U. M. J. K. I. G. U. R. Johann Große 1, "Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression," *Horm Metab Res,* 2018.
- [8] T.-M. L. G. D. E. S. O. P. Wachtel TJ, "Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island," *J Gen Intern Med,*  1991.
- [9] K. J. N. J. C. M. K. A. Umpierrez GE, " Hyperglycemic crises in urban blacks," *Arch Intern Med,* 1997.
- [10] C. C. Q. a. I. Cheikh, "History of insulin," *J Community Hosp Intern Med Perspect,* 2012.
- [11] Z. Y. G. L. G. E. A. A. Benoit SR, "Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014," *MMWR Morb Mortal Wkly Rep,* vol. 67, no. 13, 2018.
- [12] A. T. K. a. H. M. Darwish, "Diabetes mellitus: The epidemic of the century," *World J Diabetes.,* vol. 6, no. 6, 2015.
- [13] C.-S. J. W. J. d. L. S. H. A. K. K. Stone MA, "Incorrect and incomplete coding and classification of diabetes: a systematic review," *Diabet Med,* vol. 27, 2010.
- [14] T. C. P. C. O. B. F. J. L.-O. M. Thunander M, "Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden.," *Eur J Endocrinol,* 2012.
- [15] S. J. A. S. Z. P. K. G. Rosenbloom AL, "Type 2 diabetes in children and adolescents," *Pediatr Diabetes,* vol. 10, 2009.
- [16] K. S. K. D. Cakan N, "Changing spectrum of diabetes mellitus in children: challenges with initial classification.," *Clin Pediatr (Phila),* vol. 51, 2012.
- [17] Y. X. Z. G. K. G. D. D. F. T. R. M. N. J. Lamb MM, "Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young," *Diabetologia,* vol. 52, 2009.
- [18] M. A. N. V. S. J. S. J. Ferrannini E, "DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset," *Diabetes,* 2010.
- [19] H. J. T. P. T. Y. T. H. Robertson RP, "Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection.," *Diabetes,*  vol. 52, 2003.
- [20] M. R. M. S. S. J.-J. C. A. A.-A. R. A. M. K. K. S. Mizaj Shabil Sha, "Breath Analysis for the In Vivo Detection of Diabetic Ketoacidosis," *ACS Omega,* vol. 7, no. 5, 2022.
- [21] P. S. K. Y. S. M. Y. S. L. J.-K. L. S. L. M.-H. Go A, "Highly Sensitive Electrochemical Sensor for Diagnosis of Diabetic Ketoacidosis (DKA) by Measuring Ketone Bodies in Urine," *Sensors,* vol. 21, no. 14, 2021.
- [22] A. Ndiaye, S. Delile, S. Brunet, C. Varenne and A. Pauly, "Electrochemical Sensors Based on Screen-Printed Electrodes: The Use of Phthalocyanine Derivatives for Application in VFA Detection," *Biosensors,* vol. 6, no. 46, 2016.
- [23] H. J. T. P. T. Y. T. H. Robertson RP, "Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection," *Diabetes,* vol. 52, 2003.
- [24] P. K. S. Y. Z. a. M. L. F. A Sathyapalan, "Advanced selective non-invasive

ketone body detection sensors based on new ionophores," *Materials Research Express,* 2014.

- [25] K. Dhatariya, "Blood Ketones: Measurement, Interpretation, Limitations, and Utility in the Management of Diabetic Ketoacidosis," *Rev Diabet Stud,* vol. 13, no. 4, 2016.
- [26] H. R. B. Z. D.-J. S. D. R. E. D. F. E. F. V. G. A. G. G. Handelsman Y, "American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis.," *Endocr Pract.,* vol. 22, no. 6, 2016.
- [27] A. O. &. A. B. Serap Turan, "Comparison of capillary blood ketone measurement by electrochemical method and urinary ketone in treatment of diabetic ketosis and ketoacidosis in children," *Acta Diabetologica ,* vol. 45, 2008.
- [28] T. F. M. G. B. W. Joris Penders, "Quantitative measurement of ketone bodies in urine using reflectometry," *Clinical Chemistry and Laboratory Medicine,* vol. 43, no. 7, 2005.
- [29] C. M. M. B. M. Mitchell, "Utility of a Handheld Blood Ketone Meter as a Postmortem Indicator of Diabetic Ketoacidosis," *The American Journal of Forensic Medicine and Pathology,* vol. 44, no. 1, 2023.
- [30] P. C, "Postmortem diagnosis of diabetes mellitus and its complications," *Croat Med J,* vol. 56, no. 3, 2015.